National Bank of Canada FI Acquires 90,739 Shares of Moderna, Inc. (NASDAQ:MRNA)

National Bank of Canada FI grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 62.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 235,266 shares of the company’s stock after purchasing an additional 90,739 shares during the period. National Bank of Canada FI owned approximately 0.06% of Moderna worth $15,723,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Ashton Thomas Private Wealth LLC bought a new position in Moderna during the 2nd quarter valued at about $26,000. Family Firm Inc. acquired a new stake in shares of Moderna during the second quarter worth approximately $33,000. Hanseatic Management Services Inc. bought a new position in shares of Moderna in the second quarter valued at approximately $48,000. Plato Investment Management Ltd boosted its holdings in shares of Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after acquiring an additional 288 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on MRNA. TD Cowen reduced their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. The Goldman Sachs Group decreased their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $79.50.

Moderna Stock Down 9.1 %

Moderna stock opened at $41.51 on Wednesday. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market capitalization of $15.97 billion, a price-to-earnings ratio of -7.13 and a beta of 1.58. The company’s 50 day simple moving average is $49.39 and its 200 day simple moving average is $85.62.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) EPS. As a group, sell-side analysts anticipate that Moderna, Inc. will post -9.32 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,379 shares of company stock valued at $158,195. Company insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.